4-acetoxy-2-pentanone | 55577-75-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-acetoxy-2-pentanone
• 英文别名: 4-(acetyloxy)-2-pentanone；1-Methyl-3-oxo-butyl-acetat；4-acetoxy-pentan-2-one；4-Acetoxy-pentan-2-on；Methyl-(β-acetoxy-propyl)-keton；Methyl-acetonyl-carbinol-acetat；Hydracetylaceton-acetat；2-Pentanone, 4-(acetyloxy)-；4-oxopentan-2-yl acetate
• CAS: 55577-75-8
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: FTFUBYBSJNACIC-UHFFFAOYSA-N

物化性质

• 沸点：
  92 °C(Press: 20 Torr)
• 密度：
  0.993±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-acetoxy-2-pentanone 生成 4-acetoxy-pentan-2-one semicarbazone
  参考文献：
  名称：

  Nerdel et al., Journal fur praktische Chemie (Leipzig 1954), 1956, vol. <4> 3, p. 153,158

  摘要：

  DOI：
• 作为产物：
  描述：

  O-Acetyl-acetylaceton 在 Rh on carbon 氢气 作用下， 以 四氢呋喃 为溶剂， 以98%的产率得到4-acetoxy-2-pentanone
  参考文献：
  名称：

  Preparation of diastereomeric 2-deuterio-3-hydroxy butyrate. A general method for hydrogenation of β-acyloxy-α, β-unsaturated crotonates

  摘要：

  DOI：

  10.1016/s0040-4039(00)86736-2

文献信息

• A new acylation catalyst
  作者：Saeed Ahmad、Javed Iqbal

  DOI：10.1039/c39870000114

  日期：——

  Cobalt(II) chloride catalyses the acylation of alcohols and amines with anhydrides in excellent yields.

  氯化钴（II）以优异的产率催化醇和胺与酸酐的酰化反应。
• Palladium(II)-catalyzed dicarboxymethylation of chiral allylic alcohols: chirality transfer affording optically active diesters containing three contiguous chiral centers
  作者：Othman Hamed、Patrick M. Henry、Daniel P. Becker

  DOI：10.1016/j.tetlet.2010.04.105

  日期：2010.7

  This manuscript describes the extension of Stille’s palladium-catalyzed olefin dicarbonylation reaction to chiral allylic alcohols with chirality transfer to afford the corresponding chiral alcohol functionalized with bis-carbomethoxy esters, containing three contiguous chiral centers, in good to excellent diastereoselectivities (78–98%).

  该手稿描述了Stille的钯催化的烯烃二羰基化反应扩展到具有手性转移的手性烯丙基醇，从而得到相应的被双碳甲氧基酯官能化的手性醇，该手性醇包含三个连续的手性中心，具有良好的至优异的非对映选择性（78-98％） 。
• PRODRUGS OF GUANFACINE
  申请人：Whomsley Rhys

  公开号：US20110065796A1

  公开（公告）日：2011-03-17

  Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.

  本文提供了具有氨基酸或短肽的瓜那非辛前药、含有这种前药的药物组合物以及一种利用瓜那非辛前药在治疗注意力缺陷多动障碍/反抗性违抗障碍（ADHD/ODD）中提供治疗益处的方法。此外，本文还提供了减少或避免与瓜那非辛给药相关的不良胃肠道副作用的方法，以及改善瓜那非辛的药代动力学的方法。
• Stereochemical Studies of the Hydrogenation with an Asymmetrically Modified Raney Nickel Catalyst. The Hydrogenation of Acetylacetone
  作者：Akira Tai、Kazuhisa Ito、Tadao Harada

  DOI：10.1246/bcsj.54.223

  日期：1981.1

  The hydrogenation of acetylacetone (I) over asymmetrically modified Raney nickel (MRNi) proceeded, step by step, as follows: acetylacetone (I)\oversetStep 1→ 4-hydroxy-2-pentanone (II) \oversetStep 2→ 2,4-pentanediol (III). It was demonstrated that the optical yield of Step 1 and the diastereomer excess of Step 2 are governed by the ratio of the stereo-differentiating reaction site to the non-stereo-differentiating

  乙酰丙酮（I）在不对称修饰的阮内镍（MRNi）上的加氢过程如下：乙酰丙酮（I）\oversetStep 1→ 4-羟基-2-戊酮（II）\oversetStep 2→ 2,4-戊二醇 (III)。结果表明，步骤 1 的光学产率和步骤 2 的非对映异构体过量取决于催化剂上的立体差异化反应位点与非立体差异化反应位点的比率。还根据底物与吸附在催化剂上的酒石酸之间的分子间氢键模式讨论了每一步的立体化学。用酒石酸和 NaBr 的混合物 (TA-NaBr-MRNi) 改性的 RNi 在步骤 1 和步骤 2 中都得到了最好的结果。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。